Gapping down
In reaction to disappointing earnings/guidance: NMBL -45.1%, MENT -28%, WDAY -7.5%, KEYS -6.8%, ZOES -5.3%, JMEI -5.3%, ADSK -3.8%, WSM -3.3%, TFM -3%, GPS -2.8%, MOMO -1.9%, WAIR -1.4%
M&A news: DEPO -5.5% (Horizon Pharma (HZNP) withdraws offer to acquire Depomed following court ruling)
Other news: NBG -31.8% (completed the book-building process to institutional and other investors by way of a private placement of its new ordinary registered shares), APTO -26.7% (suspends clinical dosing of APTO-253 to review its drug manufacturing processes and procedures; FDA places the Phase IB clinical trial on hold), PSTG -9.8% (in symp with NMBL), BMRN -7.8% (FDA briefing docs released for co's drisapersen for DMD; evidence of efficacy is 'inconsistent and in some cases contradictory'; safety a concern), PTCT -7.6% (BMRN peer), MNKD -6.6% (CEO steps down), BLDR -4.1% ( announces the commencement of a public offering of 7 mln shares of its common stock to be sold by Warburg Pincus), AVH -3.6% (following October traffic data), LYG -2.2% (in symp with BCS dg), CLVS -1.2% (PointState Capital disclosed 7.7% stake in 13G filing), S -1.2% (signs $1.2 bln deal w/ newly formed Mobile Leasing Solutions, LLC for the sale and lease-back of certain leased devices), SNPS -1.1% (on MENT earnings/guidance), ING -0.9% (may be in symp with BCS dg)
Analyst comments: BTU -5.4% (downgraded to Sell at UBS ), EXPR -2.8% (downgraded to Sell from Neutral at Goldman), AKAM -2.6% (downgraded to Sell from Neutral at Goldman ), BCS -2.2% (downgraded to Equal-Weight from Overweight at Morgan Stanley), GRFS -1.9% (downgraded to Hold from Buy at Berenberg), AMWD -1.5% (downgraded to Neutral at Robert W. Baird
)
In reaction to disappointing earnings/guidance: NMBL -45.1%, MENT -28%, WDAY -7.5%, KEYS -6.8%, ZOES -5.3%, JMEI -5.3%, ADSK -3.8%, WSM -3.3%, TFM -3%, GPS -2.8%, MOMO -1.9%, WAIR -1.4%
M&A news: DEPO -5.5% (Horizon Pharma (HZNP) withdraws offer to acquire Depomed following court ruling)
Other news: NBG -31.8% (completed the book-building process to institutional and other investors by way of a private placement of its new ordinary registered shares), APTO -26.7% (suspends clinical dosing of APTO-253 to review its drug manufacturing processes and procedures; FDA places the Phase IB clinical trial on hold), PSTG -9.8% (in symp with NMBL), BMRN -7.8% (FDA briefing docs released for co's drisapersen for DMD; evidence of efficacy is 'inconsistent and in some cases contradictory'; safety a concern), PTCT -7.6% (BMRN peer), MNKD -6.6% (CEO steps down), BLDR -4.1% ( announces the commencement of a public offering of 7 mln shares of its common stock to be sold by Warburg Pincus), AVH -3.6% (following October traffic data), LYG -2.2% (in symp with BCS dg), CLVS -1.2% (PointState Capital disclosed 7.7% stake in 13G filing), S -1.2% (signs $1.2 bln deal w/ newly formed Mobile Leasing Solutions, LLC for the sale and lease-back of certain leased devices), SNPS -1.1% (on MENT earnings/guidance), ING -0.9% (may be in symp with BCS dg)
Analyst comments: BTU -5.4% (downgraded to Sell at UBS ), EXPR -2.8% (downgraded to Sell from Neutral at Goldman), AKAM -2.6% (downgraded to Sell from Neutral at Goldman ), BCS -2.2% (downgraded to Equal-Weight from Overweight at Morgan Stanley), GRFS -1.9% (downgraded to Hold from Buy at Berenberg), AMWD -1.5% (downgraded to Neutral at Robert W. Baird
)